WINTON GROUP Ltd Has $5.15 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

WINTON GROUP Ltd boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 169.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 38,550 shares of the life sciences company’s stock after purchasing an additional 24,249 shares during the period. WINTON GROUP Ltd’s holdings in Illumina were worth $5,151,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ILMN. Korea Investment CORP boosted its position in shares of Illumina by 92.9% during the 4th quarter. Korea Investment CORP now owns 70,588 shares of the life sciences company’s stock worth $9,433,000 after acquiring an additional 34,000 shares in the last quarter. Mendel Money Management bought a new position in shares of Illumina in the 4th quarter valued at $402,000. Murphy & Mullick Capital Management Corp acquired a new position in shares of Illumina during the 4th quarter worth $61,000. LPL Financial LLC lifted its position in shares of Illumina by 24.6% during the 4th quarter. LPL Financial LLC now owns 82,867 shares of the life sciences company’s stock worth $11,073,000 after buying an additional 16,339 shares during the last quarter. Finally, Guardian Partners Inc. bought a new position in Illumina in the fourth quarter valued at about $2,537,000. 89.42% of the stock is owned by institutional investors.

Illumina Stock Down 5.4 %

Shares of Illumina stock opened at $82.83 on Thursday. The stock’s 50-day moving average is $105.03 and its 200 day moving average is $127.40. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66. The firm has a market cap of $13.12 billion, a price-to-earnings ratio of -10.79, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ILMN shares. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their target price for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Royal Bank of Canada cut their target price on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 12th. Guggenheim dropped their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Robert W. Baird reduced their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Finally, Piper Sandler increased their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.